Portal de Periódicos da CAPES

Dupilumab‐associated facial and neck dermatitis successfully treated with baricitinib

2024; Wiley; Volume: 22; Issue: 5 Linguagem: Inglês

10.1111/ddg.15355

1610-0387

António Silva, Rita Pimenta, Ana Isabel Gouveia, Pedro Mendes‐Bastos,

Contact Dermatitis and Allergies

JDDG: Journal der Deutschen Dermatologischen GesellschaftVolume 22, Issue 5 p. 704-705 CLINICAL LETTER Dupilumab-associated facial and neck dermatitis successfully treated with baricitinib António Magarreiro-Silva, Corresponding Author António Magarreiro-Silva [email protected] orcid.org/0000-0002-0433-0352 Serviço de Dermatovenereologia, Hospital Garcia de Orta, Almada, Portugal Correspondence António Magarreiro-Silva, Hospital Garcia de Orta, Avenida Torrado da Silva, 2805-267 Almada, Portugal. Email: [email protected]Search for more papers by this authorRita Pimenta, Rita Pimenta Serviço de Dermatovenereologia, Hospital Garcia de Orta, Almada, PortugalSearch for more papers by this authorAna Isabel Gouveia, Ana Isabel Gouveia Serviço de Dermatovenereologia, Hospital Garcia de Orta, Almada, PortugalSearch for more papers by this authorPedro Mendes-Bastos, Pedro Mendes-Bastos orcid.org/0000-0002-2439-920X Dermatology Center, Hospital CUF Descobertas, Lisboa, PortugalSearch for more papers by this author António Magarreiro-Silva, Corresponding Author António Magarreiro-Silva [email protected] orcid.org/0000-0002-0433-0352 Serviço de Dermatovenereologia, Hospital Garcia de Orta, Almada, Portugal Correspondence António Magarreiro-Silva, Hospital Garcia de Orta, Avenida Torrado da Silva, 2805-267 Almada, Portugal. Email: [email protected]Search for more papers by this authorRita Pimenta, Rita Pimenta Serviço de Dermatovenereologia, Hospital Garcia de Orta, Almada, PortugalSearch for more papers by this authorAna Isabel Gouveia, Ana Isabel Gouveia Serviço de Dermatovenereologia, Hospital Garcia de Orta, Almada, PortugalSearch for more papers by this authorPedro Mendes-Bastos, Pedro Mendes-Bastos orcid.org/0000-0002-2439-920X Dermatology Center, Hospital CUF Descobertas, Lisboa, PortugalSearch for more papers by this author First published: 12 March 2024 https://doi.org/10.1111/ddg.15355Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016; 375(24): 2335-2348. 10.1056/NEJMoa1610020 CASPubMedWeb of Science®Google Scholar 2Halling AS, Loft N, Silverberg JI, et al. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. J Am Acad Dermatol. 2021; 84(1): 139-147. 10.1016/j.jaad.2020.08.051 CASPubMedWeb of Science®Google Scholar 3Jo CE, Finstad A, Georgakopoulos JR, et al. Facial and neck erythema associated with dupilumab treatment: A systematic review. J Am Acad Dermatol. 2021; 84(5): 1339-1347. 10.1016/j.jaad.2021.01.012 CASPubMedWeb of Science®Google Scholar 4Soria A, Du-Thanh A, Seneschal J, et al. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019; 155(11): 1312-1315. 10.1001/jamadermatol.2019.2613 PubMedWeb of Science®Google Scholar 5Kozera E, Stewart T, Gill K, et al. Dupilumab-associated head and neck dermatitis is associated with elevated pretreatment serum Malassezia-specific IgE: a multicentre, prospective cohort study. Br J Dermatol. 2022; 186(6): 1050-1052. 10.1111/bjd.21019 CASPubMedWeb of Science®Google Scholar 6Kozera E, Flora A, Stewart T, et al. Dupilumab-associated head and neck dermatitis resolves temporarily with itraconazole therapy and rapidly with transition to upadacitinib, with Malassezia-specific immunoglobulin E levels mirroring clinical response. J Am Acad Dermatol. 2022; 88(1): 255-257. 10.1016/j.jaad.2022.05.021 PubMedWeb of Science®Google Scholar 7Nezamololama N, Fieldhouse K, Metzger K, Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs Context. 2020; 9:2020-8-5. 10.7573/dic.2020-8-5 PubMedGoogle Scholar 8Licata G, Gambardella A, Tancredi V, et al. Face atopic dermatitis resistant to dupilumab: a case series of three patients successfully treated with upadacitinib. J Eur Acad Dermatol Venereol. 2022; 36(2): e150-e152. 10.1111/jdv.17705 CASPubMedWeb of Science®Google Scholar 9Uchida H, Kamata M, Egawa S, et al. Newly developed erythema and red papules in the face and neck with detection of demodex during dupilumab treatment for atopic dermatitis improved by discontinuation of dupilumab, switching to upadacitinib or treatment with oral ivermectin: A report of two cases. J Eur Acad Dermatol Venereol. 2023; 37(3): e300-e302. 10.1111/jdv.18743 PubMedWeb of Science®Google Scholar Volume22, Issue5May 2024Pages 704-705 ReferencesRelatedInformation